163 related articles for article (PubMed ID: 21247386)
1. Clioquinol - a novel copper-dependent and independent proteasome inhibitor.
Schimmer AD
Curr Cancer Drug Targets; 2011 Mar; 11(3):325-31. PubMed ID: 21247386
[TBL] [Abstract][Full Text] [Related]
2. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
3. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
4. The toxicology of Clioquinol.
Mao X; Schimmer AD
Toxicol Lett; 2008 Nov; 182(1-3):1-6. PubMed ID: 18812216
[TBL] [Abstract][Full Text] [Related]
5. Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer.
Daniel KG; Chen D; Yan B; Dou QP
Front Biosci; 2007 Jan; 12():135-44. PubMed ID: 17127289
[TBL] [Abstract][Full Text] [Related]
6. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma.
Mao X; Li X; Sprangers R; Wang X; Venugopal A; Wood T; Zhang Y; Kuntz DA; Coe E; Trudel S; Rose D; Batey RA; Kay LE; Schimmer AD
Leukemia; 2009 Mar; 23(3):585-90. PubMed ID: 18754030
[No Abstract] [Full Text] [Related]
7. Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents.
Oliveri V; Lanza V; Milardi D; Viale M; Maric I; Sgarlata C; Vecchio G
Metallomics; 2017 Oct; 9(10):1439-1446. PubMed ID: 28932850
[TBL] [Abstract][Full Text] [Related]
8. Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).
Zhang Z; Wang H; Yan M; Wang H; Zhang C
Mol Med Rep; 2017 Jan; 15(1):3-11. PubMed ID: 27959411
[TBL] [Abstract][Full Text] [Related]
9. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer.
Cater MA; Haupt Y
Biochem J; 2011 Jun; 436(2):481-91. PubMed ID: 21426304
[TBL] [Abstract][Full Text] [Related]
10. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Daniel KG; Chen D; Orlu S; Cui QC; Miller FR; Dou QP
Breast Cancer Res; 2005; 7(6):R897-908. PubMed ID: 16280039
[TBL] [Abstract][Full Text] [Related]
11. New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.
Chen D; Dou QP
Expert Opin Ther Targets; 2008 Jun; 12(6):739-48. PubMed ID: 18479220
[TBL] [Abstract][Full Text] [Related]
12. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.
Zhai S; Yang L; Cui QC; Sun Y; Dou QP; Yan B
J Biol Inorg Chem; 2010 Feb; 15(2):259-69. PubMed ID: 19809836
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies.
Schimmer AD; Jitkova Y; Gronda M; Wang Z; Brandwein J; Chen C; Gupta V; Schuh A; Yee K; Chen J; Ackloo S; Booth T; Keays S; Minden MD
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):330-6. PubMed ID: 22683301
[TBL] [Abstract][Full Text] [Related]
14. Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity.
Gobec M; Kljun J; Sosič I; Mlinarič-Raščan I; Uršič M; Gobec S; Turel I
Dalton Trans; 2014 Jun; 43(24):9045-51. PubMed ID: 24781711
[TBL] [Abstract][Full Text] [Related]
15. Targeting proteasomes with natural occurring compounds in cancer treatment.
Cecarini V; Cuccioloni M; Mozzicafreddo M; Bonfili L; Angeletti M; Eleuteri AM
Curr Cancer Drug Targets; 2011 Mar; 11(3):307-24. PubMed ID: 21265733
[TBL] [Abstract][Full Text] [Related]
16. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Repurposing Clioquinol for Cancer Therapy.
Khan R; Khan H; Abdullah Y; Dou QP
Recent Pat Anticancer Drug Discov; 2020; 15(1):14-31. PubMed ID: 32106803
[TBL] [Abstract][Full Text] [Related]
18. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
Crawford LJ; Walker B; Irvine AE
Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511
[TBL] [Abstract][Full Text] [Related]
20. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).
Kuhn DJ; Orlowski RZ; Bjorklund CC
Curr Cancer Drug Targets; 2011 Mar; 11(3):285-95. PubMed ID: 21247387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
